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Rheumatoid arthritis
AbstrAct
Objective to evaluate the achievement of comprehensive 
disease control (cDc) following 1 year of treatment with 
adalimumab+methotrexate versus methotrexate alone and 
whether early achievement of remission (at week 24 or 26) 
is associated with cDc at week 52 in patients with either 
early or established rheumatoid arthritis (ra).
Methods Post hoc analyses were conducted in 
three clinical studies assessing treatment with 
adalimumab+methotrexate: De019 (nct00195702) 
enrolled patients with established ra who were 
methotrexate inadequate responders; OPtiMa 
(nct00420927) and PreMier (nct00195663) enrolled 
methotrexate-naive patients with early ra. in OPtiMa, 
patients not achieving stable low disease activity at 
weeks 22 and 26 in the placebo+methotrexate group 
could receive open-label adalimumab+methotrexate 
for 52 weeks (rescue aDa arm). cDc was defined as 
the simultaneous achievement of clinical remission 
(DaS28(crP)<2.6), normal function (HaQ-Di<0.5) and 
absence of radiographic progression (ΔmtSS≤0.5).
Results regardless of disease duration, significantly 
more patients receiving adalimumab+methotrexate 
achieved cDc compared with methotrexate alone. in the 
adalimumab+methotrexate group, a numerically greater 
proportion of patients with early ra (~25%) versus 
established ra (14%) achieved cDc at 1 year; achievement 
of cDc was notably greater among patients who met 
criteria for remission at week 24 or 26 (~50% of patients 
with early ra and 39% with established ra).
Conclusion treatment with adalimumab+methotrexate 
increases the likelihood of achieving cDc in patients with 
either early or established ra. clinical remission at week 24 or 
26 is associated with achievement of cDc at week 52.
Trial registration number De019 (nct00195702), OPtiMa 
(nct00420927), PreMier (nct00195663); Post-results.
InTROduCTIOn
Rheumatoid arthritis (RA) is a chronic and 
debilitating inflammatory disease with a 
population prevalence of approximately 
1%.1 Progressive inflammation in the joints 
of patients can lead to irreversible joint 
damage2 3 and diminished function and disa-
bility.4 The primary goal of treating RA is to 
achieve a target of clinical remission, thereby 
maximising quality of life. Early diagnosis and 
treatment are important for achieving the 
elements of comprehensive disease control 
(CDC), including normalisation of physical 
function, achievement of clinical remission 
or low disease activity (LDA) and absence 
of structural damage progression through 
effective suppression of inflammation.5–7
Key messages
What is already known about this subject?
 ► clinical remission is the primary goal of treating 
rheumatoid arthritis (ra); comprehensive 
disease control (cDc) additionally encompasses 
preservation of physical function and prevention 
of structural damage progression and is a realistic 
therapeutic goal in patients with early ra.
 ► it has been unclear whether achieving clinical 
remission can predict subsequent cDc.
What does this study add?
 ► in this analysis of three studies, clinical remission at 
24 or 26 weeks was associated with achievement 
of cDc at 52 weeks.
 ► combination treatment with 
adalimumab+methotrexate (vs methotrexate 
alone) increased the likelihood of achieving cDc in 
patients with either early or established ra.
How might this impact on clinical practice?
 ► these findings may help guide treatment decisions, 
including the utility of combination treatment in 
patients with early and established ra.
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CDC is unlikely to be achievable in a large proportion 
of patients with established RA because of increasing func-
tional impairment,8 although it should constitute a realistic 
therapeutic goal in patients with early RA as suggested by 
treat-to-target recommendations,6 systematic literature 
reviews9 10 and clinical studies.11 12 Treatment recommen-
dations suggest initial treatment of active disease with 
methotrexate (MTX) monotherapy; after 6 months of 
unsuccessful treatment, a biological disease-modifying anti-
rheumatic drug (DMARD), such as a tumour necrosis factor 
(TNF) inhibitor, should be added to the therapy of patients 
with poor prognostic factors.13 Although there is evidence 
that early response or remission in RA is strongly predic-
tive of subsequent long-term remission,14–16 it is not clear to 
what extent clinical remission of RA can predict subsequent 
achievement of CDC.
The post hoc analyses detailed in this report aim to (1) 
evaluate attainment of CDC after 1 year of treatment with 
the combination of adalimumab+MTX and (2) assess 
whether the achievement of clinical remission at week 24 or 
26 is associated with CDC at week 52 in three randomised 
controlled trials in patients with early or established RA.
PaTIenTs and MeTHOds
Patients
Patient data originated from three randomised clin-
ical trials in RA: DE019 (NCT00195702),17 PREMIER 
(NCT00195663)18 and OPTIMA (NCT00420927).19 20 
All of the studies enrolled adults aged ≥18 years with 
a diagnosis of active RA as defined by the 1987 revised 
criteria of the American College of Rheumatology 
(formerly American Rheumatism Association).21 As 
noted in the original publications, an institutional 
review board or ethics committee approved the studies 
at each site.17–20
DE019 was a 1-year, phase 3, randomised, double-
blind, placebo-controlled trial of adalimumab in patients 
with RA who had active disease despite a minimum of 
3 months of treatment with MTX (MTX inadequate 
response (MTX-IR)) at a stable weekly dose of 12.5–25 mg 
(or ≥10 mg/week in those intolerant to higher doses of 
MTX) for ≥4 weeks.17 In addition, patients were required 
to have a swollen joint count based on 66 assessed joints 
(SJC66) ≥6, tender joint count based on 68 assessed 
joints (TJC68) ≥9, C-reactive protein (CRP) ≥1.0 mg/
dL, and either had to be rheumatoid factor (RF) positive 
or have ≥1 joint erosion on X-ray. Traditional DMARDs 
other than MTX were discontinued at least 28 days before 
baseline evaluations.
PREMIER was a 2-year, phase 3, randomised, double-
blind, active comparator–controlled trial of adalim-
umab in an MTX-naive population with RA disease 
duration <3 years.18 Patients were required to have 
SJC66≥8, TJC68≥10, either an erythrocyte sedimenta-
tion rate (ESR) of ≥28 mm/hour or CRP≥1.5 mg/dL, 
and either had to be RF positive or have ≥1 joint erosion 
on X-ray. Patients who had received treatment with 
MTX, cyclophosphamide, cyclosporine, azathioprine 
or >2 other DMARDs were excluded.
OPTIMA (Optimal Protocol for Treatment Initia-
tion with MTX and Adalimumab) was a 78-week, phase 
4, double-blind, randomised, placebo-controlled trial 
of adalimumab in patients with early RA with a dura-
tion <1 year and moderate or high disease activity not 
previously treated with MTX.19 20 Patients were required 
to have SJC66≥6, TJC68≥8, either an ESR of ≥28 mm/
hour or CRP≥1.5 mg/dL, and either had to be RF positive, 
anticyclic citrullinated peptide positive, or have >1 joint 
erosion on X-ray. Patients who had received previous 
MTX or other biological treatment were excluded.
Treatment regimens
In DE019, patients were randomly assigned 1:1:1 to receive 
adalimumab 40 mg subcutaneously every other week (with 
placebo injections on alternate weeks), adalimumab 20 mg 
subcutaneously weekly (not included in this analysis) or 
placebo subcutaneously weekly. The patient’s dose of 
concomitant MTX at baseline remained constant during 
the 52-week study; if toxicity occurred, the dose could be 
reduced to not lower than 10 mg weekly.
In PREMIER, patients were randomised 1:1:1 to receive 
adalimumab 40 mg subcutaneously every other week plus 
weekly oral MTX, adalimumab 40 mg monotherapy every 
other week plus weekly placebo (not included in this anal-
ysis) or weekly MTX plus placebo. MTX therapy was initi-
ated at a weekly dose of 7.5 mg for the first 4 weeks of the 
study, 15 mg weekly during weeks 4–8, then 20 mg weekly at 
week 9.
In OPTIMA, patients were randomised 1:1 to receive 
adalimumab 40 mg subcutaneously every other week plus 
weekly MTX, initiated at a dose of 7.5 mg and rapidly 
titrated to 20 mg by week 8, or placebo plus MTX for 26 
weeks (period 1). On the basis of achievement of a stable 
LDA target (28-joint Disease Activity Score based on CRP 
(DAS28(CRP)) ≤3.2 at weeks 22 and 26), placebo+MTX 
patients not achieving stable LDA (MTX-IR patients) 
received open-label adalimumab+MTX during period 2 
(Rescue ADA arm) for an additional 52 weeks. This anal-
ysis included patients in the Rescue ADA population who 
represent patients with early RA and MTX-IR.
Clinical, functional and radiographic assessments of CdC
CDC was considered the simultaneous achievement of (1) 
clinical remission, (2) normal physical function and (3) 
absence of radiographic progression. Clinical signs and symp-
toms of inflammation were assessed with the DAS28(CRP) 
or its components. The DAS28(CRP) is composed of four 
outcome variables: TJC and SJC (each based on 28-joint 
assessment), CRP and patient’s global assessment of disease 
activity on a visual analogue scale (VAS; 0–10 cm).22 Clin-
ical remission was defined as DAS28(CRP)<2.6 (OPTIMA 
and PREMIER trials).18 20 23–25 Additional post hoc analyses 
used the Simplified Disease Activity Index (SDAI), which 
is the sum of five outcome variables: TJC and SJC (each 
based on 28-joint assessment), patient and physician global 
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assessment of disease activity (VAS 0–10 cm) and CRP; a 
score of ≤3.3 indicates remission.25 26 In patients with estab-
lished RA (DE019 trial), achievement of LDA (defined as 
DAS28(CRP)≤3.2)23 27 28 rather than remission was used to 
define the clinical assessment component of CDC.
Physical function was assessed using the Health Assess-
ment Questionnaire Disability Index (HAQ-DI; score 
range, 0–3).29 Normal physical function was defined as 
HAQ-DI<0.5.30 31 To quantify structural joint damage, 
radiographs of the hands/wrists and feet were obtained 
and scored using the modified total Sharp score (mTSS) 
method.32–34 Radiographic progression of structural joint 
damage was assessed as the change from baseline (or 
from week 24/26) in mTSS (ΔmTSS). Absence of radio-
graphic progression was defined as ΔmTSS≤0.50.35
statistical analyses
The intent-to-treat population included all patients who were 
randomised and received ≥1 dose of study drug. These post 
hoc analyses assessed the proportion of patients achieving 
CDC as well as its individual components following 1 year 
of treatment with adalimumab+MTX or placebo+MTX in 
DE019 and PREMIER, and open-label adalimumab+MTX 
in the Rescue ADA arm of OPTIMA. To explore which 
component may be a limiting factor to achievement of 
CDC, frequencies of patients achieving DAS28(CRP)<2.6 
(or DAS28(CRP)≤3.2), HAQ-DI<0.5, or ΔmTSS≤0.5, and 
combinations of the targets were determined.
Last observation carried forward (LOCF) was used to 
replace missing clinical and functional data for patients 
with postbaseline assessments; non-responder imputa-
tion (NRI) was used for patients without any postbase-
line assessments. Missing Sharp scores were imputed by 
linear extrapolation for patients with baseline and post-
baseline X-rays. Patients without a postbaseline X-ray 
were considered as showing radiographic progression. 
Sensitivity analyses for radiographic non-progression 
and CDC (DAS28(CRP<2.6 or ≤3.2), HAQ-DI<0.5 and 
ΔmTSS≤0.5) based on observed data and LOCF and NRI 
data excluding patients without any postbaseline assess-
ment were used to assess the effect of missing data.
Logistic regression was used to assess the treatment 
effect on radiographic non-progression and CDC based 
on DAS28(CRP)<2.6 or ≤3.2. Generalised estimating 
equation was used to model the time-repeated measure-
ment of LDA, remission and normal function. Fish-
er’s exact test was used to assess treatment effect on 
CDC based on SDAI<3.3. There was no adjustment for 
multiple testing. Venn diagramming was used to display 
the percentages of the combination of clinical remission 
or LDA (yes/no), normal function (yes/no) and radio-
graphic non-progression (yes/no) for CDC.
ResulTs
Baseline characteristics: overall study populations
Baseline demographics and disease characteristics for 
patients receiving adalimumab+MTX or placebo+MTX 
in DE019 and PREMIER were indicative of patients with 
established and early, active RA, respectively (table 1). 
Despite an inadequate response to MTX at month 6, the 
majority of patients in the Rescue ADA arm of OPTIMA 
were in a moderate disease activity state at the time of 
open-label adalimumab initiation.
achievement of CdC at 1 year: overall patient populations
In MTX-IR patients with established RA (DE019), CDC 
based on DAS28(CRP)<2.6 was achieved in 14% (n/
N=28/207) of patients in the adalimumab+MTX arm 
compared with 3% (n/N=5/200) in the place-
bo+MTX arm (p<0.001); CDC based on SDAI≤3.3 was 
achieved in 5% (n/N=11/207) and 2% (n/N=4/207), 
respectively (figure 1A). When LDA (DAS28(CRP)≤3.2) 
was used for this population of patients with established 
disease, 19% (n/N=40/207) of patients receiving adal-
imumab+MTX achieved a CDC state at 1 year versus 
5% (n/N=10/200) of patients receiving placebo+MTX 
(p<0.001 and p=0.45; figure 1A).
In patients with early RA (PREMIER), CDC based on 
DAS28(CRP)<2.6 was achieved in 25% (n/N=67/268) 
of patients in the adalimumab+MTX arm compared with 
9% (n/N=22/257) in the placebo+MTX arm (p<0.001; 
figure 1B). Similarly, in patients with early aggressive RA 
who had inadequate response to MTX during the first 
6 months of therapy with placebo+MTX (OPTIMA), 
CDC was achieved in 24% (n/N=82/348) of patients 
after 1 year of open-label adalimumab+MTX treatment 
(figure 1C). Similar trends were observed when CDC was 
based on LDA or SDAI remission (figure 1B,C).
Consistent with the comparative treatment data for CDC 
in DE019 and PREMIER, a greater percentage of patients in 
the adalimumab+MTX arms achieved each of the individual 
components for CDC (online supplementary figures 1 and 
2). In the OPTIMA study, open-label adalimumab+MTX 
resulted in rapid improvements in clinical and functional 
components, with normal function being the more difficult 
target to reach (online supplementary figure 3).
Responder analysis: achievement of CdC and individual 
components
Post hoc analysis examining the frequency of responders 
to individual components of CDC (with the clinical 
component of remission based on DAS28(CRP)<2.6) is 
presented in Venn diagrams (figure 2). In addition to 
patients who achieved CDC by this definition, 6% (n/
N=13/207) of patients in the adalimumab+MTX arm 
satisfied the remission and radiographic non-progres-
sion criteria at year 1 vs 2% (n/N=3/200) of patients in 
the placebo+MTX arm in the DE019 study; an additional 
2% (n/N=5/207) and 1% (n/N=2/200) of patients in 
each treatment arm, respectively, also satisfied the remis-
sion and normal function criteria (figure 2A,B). In the 
PREMIER study, an additional 10% (n/N=28/268) of 
patients in the adalimumab+MTX arm and 10% (n/
N=25/257) in the placebo+MTX arm achieved remission 
and normal function criteria, and 7% (n/N=19/268) 
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and 2% (n/N=4/257), respectively, achieved remis-
sion and radiographic non-progression criteria at year 
1 (figure 2C,D). Finally, in the OPTIMA study, an addi-
tional 16% (n/N=54/348) satisfied the remission and 
radiographic non-progression criteria and 3% (n/
N=10/348) achieved remission and normal function 
criteria at year 1 (figure 2E). More patients achieved the 
clinical component of CDC when using DAS28(CRP)≤3.2 
(online supplementary figure 4) and fewer patients 
achieved the clinical component when using SDAI≤3.3 
(figure 3), shifting the distribution of responses.
Characteristics of patients achieving remission at week 24 or 
26
In the comparative studies (PREMIER (MTX-naive) and 
DE019 (MTX-IR)), patients receiving adalimumab+MTX 
were significantly more likely to achieve clinical remis-
sion at 24 or 26 weeks based on DAS28(CRP)<2.6 than 
patients receiving placebo+MTX (table 2). A compar-
ison of remission criteria revealed that at week 24 or 
26, more patients achieved a DAS28(CRP) score <2.6 
than SDAI≤3.3 in all three studies (table 2). In line with 
previous observations, the mean values for DAS28(CRP), 
mTSS and HAQ-DI for patients in clinical remission at 6 
months were generally slightly higher for patients classi-
fied as being in remission by DAS28(CRP) versus SDAI 
criteria, but this did not reach statistical difference.
achievement of CdC at 1 year: patients meeting criteria for 
remission at week 24 or 26
In the DE019 study, 39% of patients in the adalimu- 
mab+MTX arm and 33% in the placebo+MTX arm who 
met criteria for remission (DAS28(CRP)<2.6) at week 24 
achieved CDC at 1 year (figure 4A) versus 14% and 3% in the 
overall population (figure 1A). Assessing individual compo-
nents of CDC, a numerically greater proportion of patients 
achieved DAS28(CRP)<2.6 and ΔmTSS≤0.5 with adalimu- 
mab+MTX compared with placebo+MTX; however, achieve-
ment of HAQ-DI<0.5 was comparable between the treat-
ment groups. In the PREMIER study, approximately 50% of 
patients who met criteria for remission at week 26 achieved 
CDC at 1 year, regardless of treatment arm (vs 25% and 9% 
in the overall population; figures 1B and 4B). A numerically 
greater percentage of patients receiving adalimumab+MTX 
achieved DAS28(CRP)<2.6, whereas achievement of the 
other components of CDC was comparable between groups 
Table 1 Baseline demographics and disease characteristics
Characteristic*
DE019 (MTX-IR) PREMIER (MTX-naive) OPTIMA (MTX-IR†)
ADA+MTX
(n=207)
PBO+MTX
(n=200)
ADA+MTX
(n=268)
PBO+MTX
(n=257)
Rescue ADA
(n=348)
Age, year 56.1 (13.5) 56.1 (12.0) 51.9 (14.0) 52.0 (13.1) 51.2 (13.9)
Female, n (%) 158 (76) 146 (73) 193 (72) 190 (74) 266 (76)
Rheumatoid factor positive, 
n (%)
168 (81) 179 (90) 228 (85) 215 (84) 274 (79)
Duration of RA, year 11.0 (9.2) 10.9 (8.8) 0.7 (0.8) 0.8 (0.9) 0.8 (0.3)
Prior DMARD use, n (%) 207 (100) 200 (100) 87 (33) 81 (32) 348 (100)
Prior MTX dose, mg/week 17.4 (9.5) 16.8 (4.2) 0 0 19.4 (2.5)
Corticosteroid use, n (%) 90 (43) 99 (50) 96 (36) 91 (35) 149 (43)
Corticosteroid dose, mg/day 3.0 (5.8) 2.6 (6.0) 6.9 (2.5) 6.8 (3.7) 6.4 (2.2)
DAS28(CRP)
(range, 0–10)
5.6 (0.9) 5.8 (0.9) 6.3 (0.9) 6.3 (0.9) 4.5 (1.2)
DAS28(CRP)≥5.1, n (%) 150 (73) 155 (78) 230 (89) 235 (94) 111 (32)
CRP, mg/dL 1.8 (2.3) 1.8 (2.1) 3.9 (4.2) 4.0 (4.0) 1.3 (2.2)
SJC (0–66 joints) 19.3 (9.8) 19.0 (9.5) 21.1 (11.2) 22.1 (11.7) 9.4 (9.2)
TJC (0–68 joints) 27.3 (12.7) 28.1 (13.8) 30.7 (14.2) 32.3 (14.3) 16.8 (14.7)
HAQ-DI (range, 0–3) 1.5 (0.6) 1.5 (0.6) 1.5 (0.6) 1.5 (0.7) 1.1 (0.6)
mTSS (range, 0–398) 72.1 (60.7) 66.4 (47.4) 18.1 (20.1) 21.9 (22.2) 13.0 (19.5)
JE (range, 0–230) 41.4 (33.4) 37.2 (25.8) 11.0 (12.3) 13.6 (13.6) 5.9 (9.3)
JSN (range, 0–168) 30.7 (29.2) 29.2 (24.5) 7.1 (9.6) 8.2 (10.7) 7.1 (11.6)
*All values are mean (SD), unless otherwise indicated.
†OPTIMA enrolled MTX-naive patients; the Rescue ADA arm included patients treated with placebo+MTX who did not achieve stable low 
disease activity (ie, MTX-IR patients) at week 22 or 26, and received open-label ADA+MTX for an additional 52 weeks.
ADA, adalimumab; CRP, C-reactive protein; DAS28(CRP), 28-joint Disease Activity Score based on CRP; DMARD, (non-biological) disease-
modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire Disability Index; IR, inadequate response; JE, joint erosion; JSN, 
joint space narrowing; mTSS, modified total Sharp score; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis; SJC, swollen joint 
count; TJC, tender joint count.
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Figure 1 Percentage of patients achieving comprehensive disease control based on DAS28(CRP)≤3.2, DAS28(CRP)<2.6 or 
SDAI≤3.3 at week 52 in (A) DE019, (B) PREMIER and (C) the Rescue ADA arm of OPTIMA. ADA, adalimumab; DAS28(CRP), 
28-joint Disease Activity Score based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; IR, 
inadequate response; ΔmTSS, change in modified total Sharp score; MTX, methotrexate; PBO, placebo; SDAI, Simplified 
Disease Activity Index. *p<0.05 from Fisher’s exact test, ADA+MTX versus PBO+MTX. ***p<0.001 from generalised estimating 
equation or logistic regression, ADA+MTX versus PBO+MTX.
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(figure 4B). In the open-label phase of OPTIMA, approx-
imately 50% of patients who met criteria for remission at 
week 26 achieved CDC at 1 year (vs 24% in the overall popu-
lation; figure 1C), with radiographic non-progression noted 
in approximately 90% of patients (figure 4C).
When remission was defined by SDAI≤3.3, findings 
were generally comparable, although the propor-
tion of patients achieving CDC was somewhat higher 
in each of the studies (figure 4). Additionally, to 
increase the sample size of patients with established 
RA (DE019), another analysis was conducted using 
LDA as the clinical criterion at week 24 (ie, n=46 with 
DAS28(CRP)<2.6 vs n=82 with DAS28(CRP)≤3.2) and 
found that the percentage of patients achieving CDC 
at week 52 was reduced for both treatment groups 
(online supplementary figure 5).
In each of the studies, a closer examina-
tion of radiographic data among patients who 
achieved DAS28(CRP)<2.6 at week 24/26 found 
that the mean ΔmTSS from week 24/26 to week 
52 was small (online supplementary figure 6). 
Notably, a subgroup of patients in all treatment 
Figure 2 Frequency of responders to each CDC criterion (DAS28(CRP)<2.6, HAQ-DI<0.5 and ΔmTSS≤0.5) at week 52 based 
on study treatments (A) DE019, ADA+MTX; (B) DE019, PBO+MTX; (C) PREMIER, ADA+MTX; (D) PREMIER, PBO+MTX; and 
(E) OPTIMA, open-label ADA+MTX (Rescue ADA arm). ADA, adalimumab; CDC, comprehensive disease control; DAS28(CRP), 
28-joint Disease Activity Score based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; IR, 
inadequate response; ΔmTSS, change in modified total Sharp score; MTX, methotrexate; PBO, placebo.
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groups showed rapid radiographic progression 
(ie, ΔmTSS≥1.5) between week 24/26 and week 
52, with small differences between the treat-
ment groups in early RA and larger differences in 
favour of combination therapy in established RA. 
Specifically, 14% of patients receiving adalimu- 
mab+MTX (n=44) had progression at week 52 vs 22% 
of patients receiving placebo+MTX (n=9) in DE019; 
for PREMIER, percentages were 14% (n=98) vs 17% 
(n=47), respectively. In OPTIMA, 5% of patients 
receiving adalimumab+MTX (n=120) had progres-
sion at week 52.
dIsCussIOn
These post hoc analyses of the DE019, PREMIER and 
OPTIMA studies found that significantly higher rates of 
CDC were observed following 1 year of treatment with 
Figure 3 Frequency of responders to each CDC criterion (SDAI≤3.3, HAQ-DI<0.5 and ΔmTSS≤0.5) at week 52 based on 
study treatments (A) DE019, ADA+MTX; (B) DE019, PBO+MTX; (C) PREMIER, ADA+MTX; (D) PREMIER, PBO+MTX; and (E) 
OPTIMA, open-label ADA+MTX (Rescue ADA arm). ADA, adalimumab; CDC, comprehensive disease control; HAQ-DI, Health 
Assessment Questionnaire Disability Index; IR, inadequate response; ΔmTSS, change in modified total Sharp score; MTX, 
methotrexate; PBO, placebo; SDAI, Simplified Disease Activity Index.
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the combination of adalimumab+MTX than with place-
bo+MTX in MTX-IR patients with established RA and in 
patients with early RA who were MTX-naive. Overall, a 
numerically greater percentage of patients with early RA 
in PREMIER and OPTIMA met the criteria for clinical 
remission than patients with established RA in the DE019 
study. Notably, a numerically greater percentage of 
patients who were in clinical remission at 24 or 26 weeks 
achieved CDC at 1 year versus patients in the overall 
population.
Given the clinical, functional and radiographic 
non-progression efficacy demonstrated by anti-TNFs plus 
MTX compared with MTX alone in patients with active 
RA,18 20 36 37 the finding that patients treated with adali-
mumab+MTX had better outcomes than those receiving 
MTX alone in both early and established RA is not 
surprising; however, the combination of these outcomes 
(ie, CDC) had not been previously assessed.
As might be expected in more advanced disease, CDC 
was achieved in a relatively low number of patients with 
established RA compared with patients with early RA. 
Achievement of CDC in patients with established RA was 
mostly limited by achievement of DAS28(CRP)<2.6 or 
SDAI≤3.3 as the clinical component criterion (figure 2 
and 3), whereas HAQ-DI was the limiting factor when 
CDC was based on DAS28(CRP)≤3.2 (online supplemen-
tary figure 4). Based on the responder analysis, clinical 
remission was also identified as the chief limiting factor 
for achieving CDC (using DAS28(CRP)<2.6 as the clin-
ical component criterion) in patients with early RA in 
the PREMIER study, whereas achievement of normal 
physical function was limiting for patients with early 
RA in the OPTIMA study. In contrast, achieving CDC 
using SDAI≤3.3 as the clinical component criterion was 
the limiting factor in both PREMIER and OPTIMA, 
showing that the SDAI has a more stringent definition 
of remission than the DAS28(CRP). This is consistent 
with previous reports38 39 and aligns with proposals to 
change the cut-off values defining remission and LDA 
for DAS28(CRP) because the currently used values are 
too lenient.40 However, despite differences in disease 
activity level classifications, associations of SDAI and 
DAS28(CRP) remission criteria with functional status 
and joint damage progression show high accordance.38 39
Table 2 Patients in clinical remission at week 24/26 based on DAS28(CRP)<2.6 or SDAI≤3.3
DAS28(CRP)<2.6 SDAI≤3.3
ADA+MTX PBO+MTX ADA+MTX PBO+MTX
DE019 (MTX-IR) n=202 n=191 n=202 n=191
Proportion in remission at week 24 23% 5%* 10% 2%*
Characteristics of patients in remission at week 
24, mean (SD)
n=46 n=9 n=21 n=4
  DAS28(CRP) 2.11 (0.33) 2.06 (0.40) 1.88 (0.32) 1.65 (0.08)
  mTSS 57.4 (58.1) 41.4 (26.8) 45.2 (46.7) 41.6 (33.2)
  HAQ-DI 0.40 (0.45) 0.51 (0.68) 0.33 (0.41) 0.50 (0.84)
PREMIER (MTX-naive) n=267 n=252 n=267 n=252
Proportion in remission at week 26 37% 19%* 23% 12%**
Characteristics of patients in remission at week 
26, mean (SD)
n=98 n=48 n=62 n=31
  DAS28(CRP) 1.95 (0.35) 2.00 (0.35) 1.78 (0.29) 1.82 (0.27)
  mTSS 17.2 (19.4) 23.1 (24.9) 15.5 (17.0) 21.9 (28.6)
  HAQ-DI 0.25 (0.40) 0.22 (0.35) 0.18 (0.28) 0.18 (0.36)
OPTIMA (MTX-IR†) n=348 NA n=348 NA
Proportion in remission at week 26 34% NA 18% NA
Characteristics of patients in remission at week 
26, mean (SD)
n=120 NA n=61 NA
  DAS28(CRP) 2.0 (0.37) NA 1.71 (0.27) NA
  mTSS 13.4 (19.9) NA 14.9 (23.3) NA
  HAQ-DI 0.47 (0.50) NA 0.31 (0.40) NA
*p<0.0001 and **p=0.001 vs ADA+MTX, Fisher’s exact test; the last observation carried forward method was used to impute missing data for 
patients with postbaseline DAS28(CRP).
†OPTIMA enrolled MTX-naive patients; the Rescue ADA arm included patients treated with placebo+MTX who did not achieve stable low 
disease activity (ie, MTX-IR patients) at week 22 or 26, and received open-label ADA+MTX for an additional 52 weeks.
ADA, adalimumab; DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire 
Disability Index; IR, inadequate response; mTSS, modified total Sharp score; MTX, methotrexate; NA, not applicable; PBO, placebo; SDAI, 
Simplified Disease Activity Index.
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Radiographic non-progression was the least limiting 
factor for achievement of CDC in our analyses, similar 
to other studies in patients treated with a combination 
of MTX and a TNF inhibitor.12 41 This may be due to 
blockage of local TNF-α production and subsequent 
inflammatory response with TNF inhibitors compared 
with MTX alone.41 Notably, rapid radiographic progres-
sors were seen in our study; however, absolute numbers 
were low, limiting conclusions.
A targeted treatment approach in OPTIMA (aimed 
at stable LDA at 6 months) enabled 24% of MTX-IR 
patients to achieve CDC following an open-label adalimu- 
mab±MTX treatment for an additional year. In PREMIER, 
25% of MTX-naive patients with early RA who were 
receiving initial treatment with the combination of adalimu- 
mab+MTX achieved CDC at year 1. Although the numbers 
of patients who achieved CDC in PREMIER and DE019 may 
be lower than might have been achieved if these studies had 
allowed treatment adjustments for incomplete responders, 
the numbers indirectly support treat-to-target approaches to 
optimise long-term outcomes for patients with established as 
well as early RA disease.13
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Figure 4 Percentage of patients with RA achieving DAS28(CRP)<2.6 (left panel) or SDAI≤3.3 (right panel) at week 24 or 26 
who subsequently met criteria for CDC, clinical remission, non-progression of joint damage or normal physical function at 
week 52 in (A) DE019, (B) PREMIER and (C) the Rescue ADA arm of OPTIMA. The last observation carried forward imputation 
method was used for patients with missing DAS28(CRP) and HAQ-DI data. Linear extrapolation was conducted for patients 
with missing mTSS data. The non-responder imputation method was used for patients without any postbaseline DAS28(CRP), 
HAQ-DI or mTSS data. ADA, adalimumab; CDC, comprehensive disease control; DAS28(CRP), 28-joint Disease Activity Score 
based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; IR, inadequate response; ΔmTSS, 
change in modified total Sharp score; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis; SDAI, Simplified Disease 
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The notable finding that achievement of remission 
at approximately 6 months was associated with CDC at 
1 year is in line with the strong association between early 
treatment response and subsequent long-term remission 
that has been well documented in studies of patients 
with RA.14–16 42 Although no single response measure 
can reflect the full burden of RA, CDC provides a strin-
gent and comprehensive assessment of patient outcomes 
following treatment; furthermore, remission as a sole 
outcome does reflect CDC. The components of CDC 
impact each other; for example, it has been demon-
strated that joint damage is a consequence of disease 
activity and irreversible impairment of physical function 
a consequence of joint damage.43–45 Disability is also a 
consequence of both the current (reversible component) 
and past (irreversible component) disease activity, again 
highlighting the importance of achieving remission. 
Achievement of CDC has been associated with clinically 
meaningful improvements for patients in work-related 
outcomes, health-related quality of life, pain and fatigue7; 
stringent remission is similarly associated with signifi-
cant improvements in health-related quality of life and 
physical function.46 Thus, the potential for remission 
to identify patients likely to achieve CDC has important 
implications for disease management. Although there is 
evidence suggesting that an earlier time to remission is 
the strongest predictor of sustained response/remission 
in patients with RA,47 48 prospective clinical trials are 
needed to determine whether it will also be the strongest 
predictor of CDC.
The key limitation of the current report is that these 
were post hoc analyses of three individual clinical trials; 
however, although population differences prevented 
pooling of data, results were consistent among the 
trials. Nonetheless, the findings suggest that the current 
approach to comprehensive treatment deserves further 
study. Another limitation is that, although the components 
of CDC are established outcomes in clinical trials, the 
definition of CDC we used is not validated but is derived 
from treat-to-target recommendations. Debate remains 
regarding appropriate cut-off values for DAS28(CRP),13 
defined in this study as <2.6 and ≤3.2 for remission and 
LDA, respectively; SDAI was also examined because it 
has a validated cut-off for remission.49 50 Furthermore, 
addition of a workplace or social participation assess-
ment as a component of CDC may be warranted in future 
studies.42 51 In addition, the low number of patients was 
an issue in certain subgroup analyses among patients who 
achieved remission at week 24 or 26.
In conclusion, CDC appears to be a realistic treatment 
goal for many patients with early RA and established 
RA, and treatment with adalimumab+MTX appears to 
increase the likelihood of CDC. Achievement of remis-
sion at week 24 or 26 is associated with subsequent 
achievement of CDC at 1 year and thus may help guide 
treatment decisions.
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